Please assess the completion status of the following clinical trial:

Trial Title: Phase I/IIa Study of FIXFc in Hemophilia B Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Are previously treated (PTPs) with severe (\<2 IU/dL endogenous FIX level) hemophilia B and at least 150 prior documented exposure days to other FIX products.~2. Have no prior history of or currently detectable inhibitor defined as \> 0.6 Bethesda units by the local lab. A family history of inhibitors will not exclude the patient.~3. No prior history of an allergic reaction or anaphylaxis associated with any FIX or IVIG administration.~4. No concurrent autoimmune disease.~5. At least 7 days since their last dose of FIX (wash-out period).~6. Certain laboratory testing criteria and other protocol-defined criteria may apply.~7. HIV negative or if HIV positive with a CD4 count ≥ 200 cells/mm3. HIV patients are allowed to receive protease inhibitors per the discretion of the Investigator.~Key Exclusion Criteria:~1. Presence of a major bleeding episode on Day 1 of study.~2. Any coagulation disorder in addition to hemophilia B.~3. A patient currently on a dose and regimen of FIX that would preclude participation in the study due to possible increased risk of bleeding because of the requirement to withhold treatment during the study period.~4. A positive d-dimer at screening.~5. Documented history of liver cirrhosis.~6. Positive for HBsAg and/or positive for hepatitis C antibody, and/or HIV positive with an ALT or AST greater than 5 times upper limit of normal.~7. Certain prior illnesses and other protocol-defined criteria.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rFIXFc (Type: EXPERIMENTAL): Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).